Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Iruplinalkib by Qilu Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Iruplinalkib by Qilu Pharmaceutical for Non-Small Cell Lung Cancer: Likelihood of Approval
Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval
Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Iruplinalkib by Qilu Pharmaceutical for Inflammatory Myofibroblastic Tumor (IMT): Likelihood of Approval
Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Inflammatory Myofibroblastic Tumor (IMT). According to...